Centene Corporation

Centene Corporation (CNC) Market Cap

Centene Corporation has a market capitalization of $30.78B.

Price: $62.33

-0.37 (-0.59%)

Market Cap: 30.78B

NYSE · time unavailable

CEO: Sarah London

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2001-12-13

Website: https://www.centene.com

Centene Corporation (CNC) - Company Information

Market Cap: 30.78B|Sector: Healthcare

Company Profile

Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.

Analyst Sentiment

46%
Hold

From 20 Active Polls

1Y Forecast: $58.62

▼ -6.0% Potential Upside

Consensus Target Metrics

Low Bound

$39

Median

$59

High Bound

$80

Average

$59

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$58.62
▼ -5.95% Upside
Low Target
$39.00
-37% Risk
Median Target
$59.00
-5% Mid
High Target
$80.00
28% Max
Consensus
Buy
27 / 43 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)30,77816,11020,20817,52426,79030,12530,31639,29434,604
Enterprise Value ($M)25,88511,21721,09718,04929,85433,63035,68242,32234,627
Price to Earnings Ratio (P/E)-4.762.61-4.59-0.66-26.475.7426.7813.787.55
Price/Earnings-to-Growth Ratio (PEG)5.93-65.20-0.34-5.820.402.51
Price to Sales Ratio (P/S)0.160.320.410.350.550.650.740.940.87
Price to Book Ratio (P/B)1.430.751.010.840.981.081.151.441.27
Price to Free Cash Flow Ratio (P/FCF)4.854.7490.2115.3016.9921.91-40.91-34.7417.40
Enterprise Value to Sales (EV/Sales)0.220.420.360.610.720.871.010.87
Enterprise Value to EBITDA (EV/EBITDA)-5.074.96-14.95-2.92130.9415.0742.8430.0217.33
Debt to Equity Ratio0.960.760.940.840.640.660.740.640.64

CNC Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$62.33
Intrinsic Value$122.36
Market Alignment
Undervalued by 96.3%relative to calculated intrinsic value
9.00%
Exp: 12%12%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$3.35B
Perpetuity TV Value$63.05B
Discounted TV (PV)$26.63B
TV Weighting %65.2%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CENTENE CORP (CNC) — Investment Overview

🧩 Business Model Overview

Centene operates as a managed care organization (MCO), contracting with federal and state governments to administer healthcare benefits for covered populations—most prominently Medicaid and, to a lesser degree, Marketplace (ACA) and Medicare-related populations. The company acts as the intermediary between payers (government programs) and a broad provider network (physicians, hospitals, specialists, behavioral health providers, and pharmacies).

At the core of the model is risk-based, recurring revenue: Centene receives capitation or premium-like payments to manage the healthcare utilization of enrolled members. The economic engine is the spread between (1) the payments received under program rules—including risk adjustment mechanisms—and (2) the actual cost of medical services delivered. Centene seeks to improve outcomes and reduce avoidable utilization through care management, administrative operating discipline, provider contracting strategy, and pharmacy and care coordination capabilities.

Member “stickiness” is reinforced by program continuity and recertification cycles: when state contracts renew and members remain eligible, switching among plans is typically constrained by eligibility and administrative processes. For providers, Centene’s role in coordinating care and steering utilization creates operational dependence on Centene’s program design and quality frameworks.

💰 Revenue Streams & Monetisation Model

Revenue is primarily recurring and program-driven, sourced from government-sponsored premiums/capitation for covered lives. The monetisation model is less about one-off transactions and more about sustained contract administration and utilization management across enrollment cohorts.

  • Premium/capitation revenue (core): Capitated reimbursement tied to member eligibility and risk profile.
  • Risk adjustment and quality-based components: Funding that adjusts payments for expected morbidity and performance measures, influencing both top-line and relative profitability.
  • Ancillary and care services: Additional program support services and lines that can complement medical management (varies by geography and program requirements).

The primary margin drivers are the medical cost ratio (medical expense efficiency vs. earned premium), pharmacy-related costs, administrative expense discipline, and the accuracy/benefit of risk adjustment assumptions relative to actual utilization. Over time, Centene’s value creation depends on sustaining lower trend in medical costs while meeting quality and compliance benchmarks required to maintain or win contracts.

🧠 Competitive Advantages & Market Positioning

Centene’s competitive moat is rooted in regulatory and operational barriers plus scale-driven cost control. Unlike consumer subscription businesses, managed care competitiveness is heavily determined by licensing, contracting processes, compliance systems, and execution of clinical and administrative programs at scale.

Moat mechanics (why share is hard to take)

  • Regulatory moat (hard to replicate quickly): State and federal contracting requires demonstrated ability to manage populations, meet quality and reporting requirements, and comply with program integrity rules.
  • Switching frictions / contracting cycles: Even when eligibility is transferable, plan selection is constrained by bidding, contracting timelines, and performance history. Contract renewal and win rates depend on operational track record.
  • Cost and data operating leverage: Managed care scale enables better provider contracting terms, care management workflows, and utilization controls. Efficiency improvements can compound across geographies.
  • Integrated care delivery capability: Program design, care coordination, and pharmacy management reduce avoidable utilization and improve administrative throughput.

Competitive benchmarking

Centene’s industry focus is more concentrated in government-sponsored programs, particularly Medicaid and ACA-related coverage, compared with broader or different Medicare-centric strategies.

  • Molina Healthcare (MOH): Similar government-program orientation with Medicaid scale. The competitive battleground is contract awards/renewals and medical cost discipline.
  • Humana (HUM): Heavier emphasis on Medicare Advantage. The business mix and quality incentives differ, shifting focus from Medicaid risk dynamics toward Medicare star/quality measures.
  • UnitedHealth Group (UNH) — Optum: Broader ecosystem spanning insurance and care delivery/analytics. United’s integrated capabilities can pressure margin through provider and services integration at scale.

Centene’s differentiation is less about owning large provider systems and more about executing managed care under government program constraints with operating leverage, program integrity, and clinical management intensity tailored to Medicaid/Marketplace populations.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is driven by program expansion and utilization management economics rather than product novelty. Key structural drivers include:

  • Ongoing demand for government-sponsored coverage: Medicaid eligibility and ACA Marketplace enrollment dynamics support a persistent addressable market for managed care administration.
  • Improving administrative efficiency and medical cost management: Mature execution of care management and pharmacy strategies can convert membership growth into durable earnings growth when medical costs are contained.
  • Expanded value-based arrangements and care model optimization: Participation in contracted value-based care and performance-linked incentives can improve reimbursement outcomes and risk-adjusted profitability.
  • Geographic and program contract wins/renewals: Continued ability to win state bids and sustain performance under regulatory quality measures supports compounding revenue visibility.
  • Risk adjustment sophistication: The ability to correctly anticipate morbidity and align services to risk profiles can enhance margin stability as programs evolve.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: Changes in Medicaid/ACA program rules, rate setting, risk adjustment methodologies, star/quality scoring frameworks, or eligibility processes can impact revenue adequacy.
  • Medical cost trend and utilization volatility: Higher-than-expected utilization, severity shifts, or pharmacy cost inflation can pressure margins absent offsetting rate adequacy.
  • Contract concentration and bid risk: Performance under specific state contracts and the outcomes of re-bids/renewals can affect growth and earnings durability.
  • Compliance and program integrity: Managed care is sensitive to fraud/waste/abuse controls, documentation accuracy, and oversight. Compliance failures can lead to financial and operational consequences.
  • Operational and technology execution: Large-scale claims processing, care management systems, and data security create execution and cyber risk.
  • Capital and liquidity needs: MCOs must maintain required reserves and respond to regulatory capital requirements; adverse reimbursement or higher medical loss can strain capital.

📊 Valuation & Market View

Markets typically evaluate managed care insurers through a blend of earnings power and balance-sheet/capital quality rather than purely revenue growth. Common valuation frameworks include EV/EBITDA, P/E, and P/S, but the key “drivers that move the needle” are more fundamental than multiple selection:

  • Medical cost ratio durability: Trends in medical expense efficiency and the stability of the spread vs. earned premium.
  • Administrative expense leverage: Ability to grow operating income faster than underlying cost structure through scale and process discipline.
  • Risk adjustment outcomes: The extent to which program payment mechanics align with realized morbidity.
  • Quality and contract renewal confidence: Contract win rates, quality measures, and the perceived resilience to policy changes.
  • Capital adequacy and reserve strength: Insurers are valued for the capacity to absorb utilization shocks and continue contracting.

🔍 Investment Takeaway

Centene’s long-term investment case rests on a regulatory and operational moat in government-sponsored healthcare, reinforced by contracting barriers, compliance infrastructure, and scale-driven cost control. The business model monetizes the spread between program payments (including risk adjustment/quality components) and the medical cost of delivering covered care. Over time, durability depends on maintaining medical cost discipline, sustaining contract performance under evolving program rules, and executing integrated care/pharmacy management to protect profitability through enrollment and policy cycles.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CNC.

zacks.com2026-06-05

Best Growth Stocks to Buy for June 5th

PBI, CNC and HRB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 5, 2026.

zacks.com2026-06-03

Best Growth Stocks to Buy for June 3rd

PBI, CNC and MPC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 3rd, 2026.

zacks.com2026-06-01

Best Growth Stocks to Buy for June 1st

PBI, CNC and MPC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 1st, 2026.

zacks.com2026-05-28

Centene (CNC) Up 9% Since Last Earnings Report: Can It Continue?

Centene (CNC) reported earnings 30 days ago. What's next for the stock?

zacks.com2026-05-28

Best Growth Stocks to Buy for May 28th

PBI, CNC and MPC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 28, 2026.

zacks.com2026-05-27

Why Centene (CNC) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

prnewswire.com2026-05-26

Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating

"America's Best Customer Service in Financial Services 2026" award recognizes companies delivering strong customer service based on nationwide consumer feedback SACRAMENTO, Calif., May 26, 2026 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and company of Centene Corporation (NYSE: CNC), has been named one of America's Best Customer Service in Financial Services 2026, a national recognition published by USA TODAY in partnership with independent research firm Plant‑A Insights Group.

zacks.com2026-05-26

Best Growth Stocks to Buy for May 26th

CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.

247wallst.com2026-05-20

Here Are Wednesday’s Top Wall Street Analyst Research Calls: BJ’s Wholesale Club, Centene, Cigna, Crown Castle, ETSY, Franco-Nevada, Humana, Ovintiv, X-Energy, and More

Pre-Market Stock Futures: Futures are trading higher on the heels of the third straight day of stock declines, and there is growing apprehension that yields will go even higher and that inflation may as well. All of the major indices finished Tuesday lower, and with Q1 earnings all but over and the incoming economic data... Here Are Wednesday's Top Wall Street Analyst Research Calls: BJ's Wholesale Club, Centene, Cigna, Crown Castle, ETSY, Franco-Nevada, Humana, Ovintiv, X-Energy, and More

prnewswire.com2026-05-12

Superior HealthPlan Awards $100,000 in Grants to 10 Community-based Organizations in Texas

The funding is made available through an annual program that addresses barriers to healthcare. AUSTIN, Texas, May 12, 2026 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), has announced the 2026 recipients of its annual grant program.

zacks.com2026-05-07

Has Centene (CNC) Outpaced Other Medical Stocks This Year?

Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

zacks.com2026-05-07

Best Growth Stocks to Buy for May 7th

CNC, WOOF and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 7, 2026.

zacks.com2026-05-07

Best Value Stocks to Buy for May 7th

CNC, SLDE and UVE made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 7, 2026.

zacks.com2026-05-07

New Strong Buy Stocks for May 7th

CSTM, CNC, TEAM, WDC and COLM have been added to the Zacks Rank #1 (Strong Buy) List on May 7, 2026.

zacks.com2026-05-05

Here's Why Centene (CNC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CNC reported Q1 2026 revenue of $49.94B and net income of $1.54B (EPS $3.13). On a YoY basis, revenue increased from $46.62B in Q1 2025 to $49.94B in Q1 2026 (+7.1% YoY), while net income rose from $1.31B to $1.54B (+17.6% YoY). QoQ performance improved sharply: revenue was up slightly vs. Q4 2025 ($49.94B vs. $49.73B, +0.4% QoQ), but net income swung from a loss in Q4 2025 (-$1.10B) to a profit (+$1.54B), indicating major stabilization in profitability. Margins expanded over the last four quarters: gross margin improved materially (Q1 2026 21.9% vs. 15.2% in Q4 2025), and net profit margin moved from negative (Q4 2025 -2.2%, Q3 2025 -13.3%) back to positive (+3.1% in Q1 2026). Operating cash flow was strong at $3.60B and free cash flow at $3.40B. The balance sheet remains resilient with total assets of $81.2B and equity of ~$21.4B; leverage is moderate and net cash remains (net debt improved to -$4.9B vs. +$0.9B in Q4 2025). Total shareholder return is mixed: the stock price is $38.17 and the 1-year change is -38.42% (capital appreciation negative). There is no dividend paid in the data provided (payout ratio 0), and buybacks were minimal ($29M repurchased). Valuation indicators show low P/E on positive earnings (P/E ~2.6) but sentiment appears subdued given the sharp 1Y decline."

Revenue Growth

Positive

Revenue grew +7.1% YoY (Q1 2025 $46.62B to Q1 2026 $49.94B) and was flat-to-up QoQ (+0.4% vs Q4 2025 $49.73B).

Profitability

Good

Net income improved +17.6% YoY (to $1.54B) and flipped QoQ from -$1.10B in Q4 2025 to +$1.54B. Margins rebounded strongly: gross margin 21.9% (vs 15.2% in Q4) and net margin +3.1% (vs -2.2% in Q4).

Cash Flow Quality

Positive

Operating cash flow was $3.60B and free cash flow $3.40B in Q1 2026, vs much weaker/negative earnings in prior quarters. No dividends were paid; buybacks were negligible.

Leverage & Balance Sheet

Neutral

Balance sheet size increased (assets $81.2B vs $77.7B in Q4). Equity rose to ~$21.4B. Net debt turned to net cash (-$4.9B) from net debt in Q4 (+$0.9B).

Shareholder Returns

Neutral

1Y price change is -38.42%, indicating negative capital appreciation. Dividend yield is 0% in the dataset and buybacks were small, so total returns are weak despite improved fundamentals.

Analyst Sentiment & Valuation

Neutral

Consensus price target is $45 vs current $38.17 (~+18% upside). Valuation looks supportive on earnings (P/E ~2.6), but recent profitability volatility may temper sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Centene’s Q1 2026 performance was a clear beat: adjusted EPS of $3.37 and consolidated HBR of 87.3%, with Medicaid and Medicare Advantage/PDP all exceeding expectations. Medicaid improved to 93.1% HBR (+50 bps YoY), driven by scaled trend management (utilization management standardization, clinical program scaling, network optimization) and continued payment-integrity/fraud-waste-abuse efforts; flu and weather helped but management emphasized fundamental execution. Medicare printed 84.9% HBR and management leaned into a credible 2027 breakeven path, supported by execution during AEP/OEP and specialty pharmacy trend coming in softer than forecast. Marketplace guidance is more guarded: pretax margin embedded at ~3% vs ~4% prior, reflecting only a partial risk adjustment receivable pending June Wakely data. Capital actions were supportive but should be modeled: $1B Part D receivable sales funded $1B senior note repurchases, lowering debt-to-cap to 43.2%. Net outlook: positive momentum in operating metrics, but risk-transfer validation (June) and Medicaid work-requirement acuity remain key watch items.

AI IconGrowth Catalysts

  • Medicaid HBR progress to 93.1% (+50 bps YoY Q1) driven by scaled trend-management: network optimization, clinical programs, and expanded payment-integrity/fraud-waste-abuse initiatives
  • Medicare segment outperformance with consolidated HBR 84.9% (MA + PDP exceeding expectations) from bid/trend execution and early 2026 pharmacy/specialty drug trend coming in below forecast
  • Marketplace margin support from improved SG&A discipline offsetting slightly higher utilization in Silver; expectation of meaningful risk-adjustment offset as risk scores track claims

Business Development

  • CMS Bridge program: Centene highlighted offering participation for Medicare members and engagement on GLP-1 access and future balance model positioning
  • Wakely actuarial collaboration: Centene enabled earlier aggregation/publication of interim risk transfer/risk-score demographic data across ~29 markets (end of March) used to refine Marketplace risk adjustment assumptions
  • CMS RFI referenced for Medicaid program-integrity reforms (proactive payment suspensions, safe harbors, and 2-way data sharing); Centene plans to partner in states to protect taxpayer dollars and improve program integrity

AI IconFinancial Highlights

  • Adjusted diluted EPS: $3.37 in Q1 2026, about $0.50 above expectations; full-year 2026 adjusted EPS increased to >$3.40 (from >$3.00 previously)
  • Consolidated HBR: 87.3% for Q1
  • Medicaid HBR: 93.1% in Q1, +50 bps improvement vs Q1 2025; management expects ability to outperform 93.7% implied level and cited flu and weather as partial contributors but emphasized underlying execution
  • Medicare HBR: 84.9% in Q1; management confidence on MA path to 2027 breakeven
  • Marketplace: guidance embed of ~3% pretax margin vs prior ~4%; calibrated to assume only a partial risk adjustment offset (slight receivable vs prior payable) pending June Wakely data
  • SG&A efficiency: consolidated SG&A expense ratio 7.6% in Q1 vs 7.9% in 2025 (−30 bps)

AI IconCapital Funding

  • $1.0B sale of stand-alone 2025 Part D risk share receivables in Q1
  • $1.0B repurchase of senior notes funded by receivable sale proceeds (debt-to-cap 43.2% down from 46.5% at year-end; −330 bps)
  • Cash available for general corporate use: $437M at quarter end
  • Medical claims payable: $20.6B representing 48 days in claims payable (+2 days vs Q4 2025)
  • Operating cash flow: $4.4B in Q1, driven by net earnings and partial 2025 CMS PDP receivable sale plus timing of other cash flows
  • Debt maturities flagged for modeling: December 2027 and summer 2028; management indicated intent to refinance and evaluate partial balance modifications

AI IconStrategy & Ops

  • Medicaid: multipronged trend program scaled since back half of 2024; standardized utilization management, expanded clinical programs, data-driven network optimization, state-partner advocacy, and aggressive fraud/waste/abuse stamping out
  • ABA program integrity: management cited >1 year of data with stabilizing YoY ABA trends attributed to ensuring appropriate high-quality care for ABA members and improved outlier-provider identification
  • Medicare: simplified contract structure and focused partner ecosystem for value-based care; deployed total cost of care models for oncology, chronic kidney disease, and behavioral health specialties
  • Marketplace: risk visibility improved via earlier Wakely reporting; Silver retention viewed as intentionally less aggressive than competitors (and positioned for risk adjustment receivables)

AI IconMarket Outlook

  • Medicaid: guidance assumes net trend (medical costs net of initiatives) in the mid-4% range; composite rate yield around ~4.5%
  • Medicaid full-year HBR guidance: 90.9% to 91.7% (no change reported); guidance messaging indicates possible beat vs 93.7% level referenced for Q1 context
  • Marketplace: June Wakely data expected to refine risk adjustment assumptions; current guidance reflects a prudent posture not booking full risk adjustment magnitude suggested by available data
  • Marketplace membership: ended Q1 with 3.58M; expects a little attrition to end 2026 at a little over 3.0M
  • Medicare: emphasized path to breakeven in 2027; management noted finalized 2027 MA rates improved versus advanced rate notice (still below observed trend)

AI IconRisks & Headwinds

  • Marketplace underwriting/risk transfer uncertainty: guidance does not reflect full risk adjustment offset implied by earlier data; June Wakely risk score/claims data is key to validate margin assumptions
  • Medicaid: elevated behavioral health and high-cost drug environment persists; management noted trend is still elevated vs historical baseline and expects pockets of deceleration consistent with maturation from 2025 into 2026
  • Medicaid work requirement implementation risk: rate-setting discussions must consider potential acuity shifts; management highlighted Nebraska as an early mover into 2026 and noted CMS guidance on OB3/work requirements and expectation management
  • Debt/refinancing risk: sizable 2027 and 2028 maturities (December 2027; summer 2028) may require refinancing depending on rates and preferred capital structure
  • Claims payable days increased by 2 days to 48 (cash timing/claims liability dynamics can affect near-term liquidity modeling)

Q&A: Analyst Interest

  • Marketplace Silver acuity and risk adjustment: Topic: Management explained the higher Silver cohort in 2026 as a post-enhanced-APTC market shift where Silver membership remained relatively more acute due to Centene’s less aggressive AMBR strategy and risk-pool mechanics; they said guidance assumes only a partial risk adjustment receivable ahead of June Wakely.
  • Medicaid HBR drivers and glide path: Topic: Management confirmed Q1 Medicaid outperformance versus mid-4% net trend and ~4.5% rate yield assumptions was partly flu/weather but also driven by underlying program execution (network optimization, clinical programs, and payment integrity). They said the forecast for the rest of 2026 isn’t counting on continued outsized flu/weather benefit.
  • Risk adjustment booking scope across the book and Medicare/Part D margin trajectory: Topic: Management clarified the slight receivable position in Marketplace is across the whole book because risk adjustment is agnostic of metal tier; they did not book full suggested receivable magnitude. They also stated Medicare Advantage and PDP full-year margins should land slightly better, without assuming continued quarterly outperformance.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CNC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CNC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CNC)

© 2026 Stock Market Info — Centene Corporation (CNC) Financial Profile